Monthly Archives

September 2021

BLACKHAWK GROWTH’S MINDBIO THERAPEUTICS SIGNS COLLABORATION AGREEMENT WITH DIGITAL MIND TECHNOLOGY TECHNOLOGY

Vancouver, British Columbia – September 29, 2021 – Blackhawk Growth Corp. (CSE:BLR; Frankfurt:0JJ) (the “Company” or “Blackhawk”) is pleased to announce that its subsidiary, MindBio Therapeutics, has signed an agreement with Digital Mind Technology Pty Ltd, (“Digital Mind”) a medical research and technology company developing evidence-based digital interventions to improve mental health and wellbeing. The agreement will see the two…

Read More

Blackhawk’s MindBio Therapeutics Utilizes Trip Pharma to Bring Microdosing Trials to North America

Vancouver, British Columbia – TheNewswire – September 23, 2021 – Blackhawk Growth Corp. (CNSX:BLR.CN) (OTC:BLRZF) (Frankfurt:0JJ) (the “Company” or “Blackhawk”) is pleased to announce that its subsidiary Trip Pharma, a Psychedelic Development and Wellness Company and operator of LeichtMind multidisciplinary clinics, has partnered with MindBio Therapeutics to launch MindBio’s microdosing trials in Canada. MindBio Therapeutics, a 100% owned subsidiary of…

Read More

Blackhawk Growth’s MindBio Therapeutics Plans to Commercialize Intellectual Property Generated from the University of Auckland’s Clinical Trial in Psychedelic Assisted Therapy in Advanced Stage Cancer Patients

   Vancouver, British Columbia – TheNewswire – September 16, 2021 – Blackhawk Growth Corp. (CSE:BLR); (CNSX:BLR.CN); (OTC:BLRZF); (Frankfurt:0JJ) (the “Company” or “Blackhawk”) is pleased to provide an update on MindBio Therapeutics Pty Ltd. (“MindBio Therapeutics”), a clinical stage drug development company conducting research into microdosing and medicinal use of psychedelic medicine.    MindBio Therapeutics plans to commercialize the intellectual property…

Read More

Blackhawk Growth’s MindBio Therapeutics Opens World Class Facility for the Pharmaceutical Industry

Vancouver, British Columbia – TheNewswire – September 13, 2021 – Blackhawk Growth Corp. (CNSX:BLR.CN) (OTC:BLRZF) (Frankfurt:0JJ) (the “Company” or “Blackhawk”) is pleased to provide an update on MindBio Therapeutics Pty Ltd. (“MindBio Therapeutics”), a clinical stage drug development company conducting research into microdosing and medicinal use of psychedelic medicine.    MindBio Therapeutics is excited to announce that it will open…

Read More

Blackhawk Growth’s SAC Pharma Announces Record August Revenue of CDN$460,000 and Includes Operational Update

Vancouver, British Columbia – TheNewswire – September 09, 2021 – Blackhawk Growth Corp. (CSE:BLR) (CNSX:BLR.CN) (Frankfurt:0JJ) (OTC:BLRZF) (the “Company”), is excited to announce the record unaudited revenue in the month of August for Sac Pharma Partners USA (“SAC Pharma”), its wholly owned subsidiary, of CDN$460,000. Sac Pharma continues to show strong revenue growth. Revenue for the 8 months ended August…

Read More

Blackhawk Growth Subsidiary, MindBio Therapeutics, Accelerates Phase 1 & Phase 2 Microdosing Clinical Trials

Vancouver, British Columbia – TheNewswire – September 07, 2021 – Blackhawk Growth Corp. (CNSX:BLR.CN) (OTC:BLRZF) (Frankfurt:0JJ) (the “Company” or “Blackhawk”) is pleased to provide an update on its most recent investment, MindBio Therapeutics Pty Ltd. (“MindBio Therapeutics”), a clinical stage drug development company conducting research into microdosing and medicinal use of psychedelic medicines to treat a range of debilitating mental…

Read More

Blackhawk Growth Closes Investment in Psychedelic and Wellness Company MindBio Therapeutics Pty Ltd.

  Vancouver, British Columbia – September 03, 2021 – Blackhawk Growth Corp. (CSE:BLR) (CNSX:BLR.CN) (Frankfurt:0JJ) (the “Company” or “Blackhawk”) has completed its previously announced investment in MindBio Therapeutics Pty Ltd. (“MindBio Therapeutics”).     “I am extremely excited to see us complete this transaction” says Frederick Pels, CEO of Blackhawk. “I look forward to working with the team at MindBio…

Read More